Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar;22(1):125-135.
doi: 10.1111/vco.12960. Epub 2024 Jan 21.

Outcomes of 35 dogs with craniomaxillofacial osteosarcoma treated with stereotactic body radiation therapy

Johnny Altwal  1 , Ber-In Lee  2 , Mary-Keara Boss  2 , Susan M LaRue  3 , Tiffany Wormhoudt Martin  2
Affiliations

Outcomes of 35 dogs with craniomaxillofacial osteosarcoma treated with stereotactic body radiation therapy

Johnny Altwal et al. Vet Comp Oncol. 2024 Mar.

Abstract

Canine craniomaxillofacial osteosarcoma (OSA) is most commonly treated surgically; however, in cases where surgery is not feasible or non-invasive treatment is desired, stereotactic body radiation therapy (SBRT) may be elected for local tumour control. In this study, we evaluated 35 dogs treated with SBRT. Nine dogs (26%) had calvarial, seven (20%) had mandibular and 19 (54%) had maxillary OSA. Median time to first event (TFE) was 171 days, and overall median survival time (MST) was 232 days. Site-specific MSTs were 144 days for mandible, 236 days for calvarium and 232 days for maxilla (p = .49). Pulmonary metastatic disease was observed in 12/35 (34%) patients and was detected pre-SBRT in six dogs (17%) and post-SBRT in the remaining six dogs (17%). Eighteen adverse events post-SBRT were documented. Per veterinary radiation therapy oncology group criteria, five were acute (14%) and three were late (9%) grade 3 events. Neurological signs in two dogs were suspected to be early-delayed effects. Cause of death was local progression for 22/35 (63%) patients, metastasis for 9/35 (26%) patients and unknown for four. On univariate analysis, administration of chemotherapy was associated with a longer TFE (p = .0163), whereas volume of gross tumour volume was associated with a shorter TFE (p = .023). Administration of chemotherapy and five fractions versus single fraction of SBRT was associated with increased survival time (p = .0021 and .049). Based on these findings, a treatment protocol incorporating chemotherapy and five fractions of SBRT could be considered for dogs with craniomaxillofacial OSA electing SBRT with careful consideration of normal tissues in the field.

Keywords: canine; craniomaxillofacial; osteosarcoma; radiotherapy; stereotactic.

PubMed Disclaimer

References

REFERENCES

    1. Mason NJ. Comparative immunology and immunotherapy of canine osteosarcoma. In: Kleinerman ES, Gorlick R, eds. Current Advances in the Science of Osteosarcoma: Research Perspectives: Tumor Biology, Organ Microenvironment, Potential New Therapeutic Targets, and Canine Models. Springer International Publishing; 2020:199-221.
    1. Heyman SJ, Diefenderfer DL, Goldschmidt MH, Newton CD. Canine axial skeletal osteosarcoma. A retrospective study of 116 cases (1986 to 1989). Vet Surg. 1992;21(4):304-310.
    1. Thompson KG, Pool RR. InIn: Meuten DJ, ed. Tumors in Domestic Animals. 2nd ed. Iowa State Press; 2002:263-283.
    1. Schwarz PD, Withrow SJ, Curtis CR, Powers BE, Straw RC. Mandibular resection as a treatment for oral cancer in 81 dogs. J Am Anim Hosp Assoc. 1991;27:601-610.
    1. Schwarz PD, Withrow SJ, Curtis CR, Powers BE, Straw RC. Partial maxillary resection as a treatment for oral cancer in 61 dogs. J Am Anim Hosp Assoc. 1991;27:617-624.

LinkOut - more resources